Clinical Trials Logo

Pancreas Adenocarcinoma clinical trials

View clinical trials related to Pancreas Adenocarcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04241367 Active, not recruiting - Clinical trials for Pancreas Adenocarcinoma

Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy

Start date: March 28, 2019
Phase:
Study type: Observational

This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.

NCT ID: NCT03472716 Active, not recruiting - Clinical trials for Pancreas Adenocarcinoma

The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma (BIGHPANC)

BIGHPANC
Start date: May 22, 2018
Phase:
Study type: Observational

The primary objective of this trial is to evaluate the correlation between the intensity of the protein big-h3 expression at tumoural microenvironment and the TNM/UICC staging (from I to IV) of pancreatic adenocarcinoma lesion.

NCT ID: NCT03377491 Active, not recruiting - Clinical trials for Pancreas Adenocarcinoma

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

Start date: February 10, 2018
Phase: Phase 3
Study type: Interventional

Brief Summary: The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.